Table 2 Relationship between the expression of PINK1 and PARK2 and clinicopathological characteristics of the ESCC patients

Sex

0.296

0.587

1.080

0.303

 Male

157

100 (63.7)

57 (36.3)

99 (63.1)

58 (36.9)

 Female

75

45 (60.0)

30 (40.0)

42 (56.0)

33 (44.0)

Age

0.117

0.733

0.296

0.586

 < 60

102

65 (63.7)

37 (36.3)

64 (62.7)

38 (37.3)

 ≥ 60

130

80 (61.5)

50 (38.5)

77 (59.2)

53 (40.8)

Location

0.420

0.517

3.190

0.074

 Up and middle

129

83 (64.3)

46 (35.7)

85 (65.9)

44 (34.1)

 Low

103

62 (60.2)

41 (39.8)

56 (54.4)

47 (45.6)

Tumor size

1.797

0.180

0.966

0.326

 ≤ 3 cm

68

38 (55.9)

30 (44.1)

38 (55.9)

30 (44.1)

 > 3 cm

164

107 (65.2)

57 (34.8)

103 (62.8)

61 (37.2)

Grade^a

7.107

0.029*

1.551

0.460

 G1

35

15 (42.9)

20 (57.1)

18 (51.4)

17 (48.6)

 G2

148

96 (64.9)

52 (35.1)

93 (62.8)

55 (37.2)

 G3

49

34 (69.4)

15 (30.6)

30 (61.2)

19 (38.8)

T stage

5.623

0.018*

1.823

0.177

 T1–T2

97

52(53.6)

45(46.4)

54 (55.7)

43 (44.3)

 T3–T4

135

93(68.9)

42(31.1)

87 (64.4)

48 (35.6)

Lymph node metastasis

3.231

0.072

4.265

0.039*

 N0

113

64 (56.6)

49 (43.4)

60 (53.1)

52 (46.9)

 N1

119

81 (68.1)

38 (31.9)

80 (67.2)

39 (32.7)

Metastasis

0.932

0.334

1.135

0.287

 M0

223

138 (61.9)

85 (38.1)

134 (60.1)

89 (39.9)

 M1

9

7 (77.8)

2 (22.2)

7 (77.8)

2 (22.2)

TNM stage^b

5.225

0.022*

4.230

0.040*

 I-II

103

56 (54.4)

47 (45.6)

55 (53.4)

48 (46.6)

 III-IV

129

89 (69.0)

40 (31.0)

86 (66.7)

43 (33.3)